Wallets at Novo Nordisk might get fatter if enduring weight loss becomes the primary treatment goal for people with type 2 diabetes, as several researchers have proposed in the Lancet, Danish business daily Børsen reports on Wednesday.
A person with type 2 diabetes who loses 15 percent of their bodyweight could see disease-altering effects, and the drugs Saxenda and the more recently launched Wegovy from Novo Nordisk are excelling in their ability to reduce bodyweight in obese patients by over 15 percent over a longer period.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
Long wait for IVDR implementation is over, putting an end to pandemic "wild west"
After prolonged debates on potential bottlenecking and supply issues, the EU’s long-awaited In Vitro Diagnostic Medical Devices Regulation comes into force on May 26.
Bavarian Nordic upgrades guidance following vaccine contract
Bavarian has been the center of attention in recent days due to its monkeypox vaccine, and the company has now secured a vaccine contract with another undisclosed country. Consequently, Bavarian has raised its expectations for the full year.
US to start using Bavarian vaccine stockpile
In an attempt to contain a monkeypox outbreak, US authorities will start offering certain people Bavarian Nordic-developed Jynneos vaccinations against the infectious disease.
GN purchase story is very speculative, says analyst
Competition rules could block a purchase of GN Store Nord and subsequent divestment of GN Hearing, says a Sydbank analyst on the speculative story that this might be underway.
Novo Nordisk invests additional millions of dollars in new manufacturing facilities
Novo Nordisk’s DKK 17bn (USD 2.4bn) investment into upgrading and building new facilities in Kalundborg last year has now been followed by a DKK 1bn (USD 143.8m) investment in the same location.
Senior Chemical Safety Advisor 
Communications Consultant 
2 Sales Representatives and Product Specialists 
Director of Toxicology 
Analytical Senior Scientist 
Senior Manager, Clinical Trial Budget 
KLIFO is looking for a Clinical Supply Manager for our Glostrup office 
(Senior) Drug Substance Specialist 
Clinical Trial Manager for development of in vitro diagnostics 
CMO Operations Specialist - screening & selection of CMO/CDMO’s 
Director for innovative pre-clinical testing unit 
Strategic Procurement Manager, Direct Spend (Category Manager) 
Clinical Project Manager 
Chemist for Incoming Materials in QC Department 
Production Director 
Account Manager